Adjuvant Systemic Therapy and Treatment of Locally Advanced Non-Small Cell Lung Cancer

Approximately what percent of the time do you use the following chemotherapy regimens for adjuvant treatment of non-small cell lung cancer (NSCLC)?

Approximate percent of the time the following platinum-based chemotherapy regimens for adjuvant treatment of NSCLC are used:

Would you generally recommend adjuvant chemotherapy for a 60-year-old patient, PS 0/1 with the following node-negative tumors?

Would you generally recommend adjuvant chemotherapy for a 60-year-old patient, PS 0/1 with the following node-negative tumors? (continued)

Would you generally recommend adjuvant chemotherapy for patients with the following types of node-positive lung cancer?

How do you utilize erlotinib after resection of Stage II NSCLC in the following scenarios?

How do you utilize erlotinib after resection of Stage II NSCLC in the following scenarios? (continued)

How do you utilize erlotinib after resection of Stage II NSCLC in the following scenarios? (continued)

How do you utilize erlotinib after resection of Stage II NSCLC in the following scenarios? (continued)

How do you utilize erlotinib in the treatment of a patient with unresectable Stage III NSCLC after definitive chemoradiation therapy?

How do you utilize erlotinib in the treatment of a patient with unresectable Stage III NSCLC after definitive chemoradiation therapy? (continued)

RADIANT: A randomized Phase III study of erlotinib with or without adjuvant chemotherapy for patients with EGFR-positive NSCLC

A 65-year-old man who is a 40 pack-year smoker with unresectable Stage IIIA adenocarcinoma (bulky ipsilateral mediastinal nodes) and no weight loss presents for your opinion regarding the management of his lung cancer. What is your recommendation for this patient?

For a patient with a good performance status and unresectable Stage IIIB NSCLC treated with concurrent chemoradiation therapy, would you recommend docetaxel consolidation therapy after chemoradiation therapy?

Randomized, Phase III, placebo-controlled trial of sunitinib as maintenance therapy in nonprogressing disease after an initial four cycles of platinum-based combination chemotherapy in advanced Stage IIIB/IV NSCLC